FDA has issued an emergency use authorization (EUA) for the Cobas SARS-CoV-2 test, from Roche, Basel, Switzerland.
The test is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19, in nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical or epidemiological criteria for testing. Hospitals and reference laboratories can run the test on Roche’s fully automated Cobas 6800 and Cobas 8800 systems, which are widely available in the United States and around the world.

The CE marked test is also available in markets accepting the CE mark for patients with signs and symptoms of COVID-19 disease and living in affected areas where the SARS-CoV-2 virus is known to be present.


Thomas Schinecker, Roche Diagnostics.

“Providing quality, high-volume testing capabilities will allow us to respond effectively to what the World Health Organization has characterized as a pandemic. It is important to quickly and reliably detect whether a patient is infected with SARS-CoV-2,” says Thomas Schinecker, PhD, chief executive officer of Roche Diagnostics. “Over the last weeks, our emergency response teams have been working hard to bring this test to the patients. CE mark certification and the FDA’s granting of EUA supports our commitment to give more patients access to reliable diagnostics which are crucial to combat this serious disease.”

The widely available Roche Cobas 6800 and Cobas 8800 systems provide test results in 3.5 hours and offer improved operating efficiency, flexibility, and fastest time-to-results, with the highest throughput providing up to 96 results in about 3 hours. Daily 24-hour throughput totals 1,440 results for the Cobas 6800 system and 4,128 results for the Cobas 8800 system. The SARS-CoV-2 test can be run simultaneously with other assays provided by Roche for use on the Cobas 6800 or Cobas 8800 systems.

Upon authorization, Roche will have millions of tests a month available for use on the Cobas 6800 and Cobas 8800 systems. Roche is committed to delivering as many tests as possible and is going to the limits of its production capacity.

For more information, visit Roche.